Lilly basal insulin beats Lantus

In two Phase 3 clinical trials, Eli Lilly's (NYSE:LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared to Sanofi's (NYSE:SNY) Lantus (insulin glargine) at 26 and 52 weeks in patients with Type 1 diabetes.

Both trials showed the rate of nocturnal hypoglycemia was significantly lower in patients taking BIL than those taking insulin glargine. In the open-label IMAGINE-1 trial, patients taking BIL reported a statistically significant higher rate of severe hypoglycemic events, however. In the the larger blinded IMAGINE-3 trial, the rate of severe hypoglycemic events in patients taking BIL was numerically lower that the insulin glargine arm but it was not statistically significant.

Both trials showed a statistically significant difference in weight. The BIL cohort experienced weight loss with lower HbA1c compared to weight gain in the insulin glargine cohort.

In IMAGINE-3, the BIL cohort showed statistically significant changes compared to insulin glargine in certain parameters: an increase in triglycerides and LDL cholesterol, a decrease in HDL cholesterol and increases in systolic and diastolic blood pressure. Some of these changes were not observed in IMAGINE-1.

Lilly intends to submit its marketing application with regulators in Q1 2015.

From other sites
Comments (3)
  • 487371
    , contributor
    Comments (13) | Send Message
    most likely, the minor differences cited are of little, if any, clinical significance related to overall health. Likely that they are simply an attempt by Lilly to recapture a patent monopoly on insulin products, as generics will be replacing the current novalog/humalog price-fixing scheme. They hope that the medico-legal system will force doctors to prescribe these "new" products based on their (likely) hyped results.
    5 Sep 2014, 08:26 AM Reply Like
  • bob1058
    , contributor
    Comments (12) | Send Message
    I suggest you do some researcg rather than just make speculative statements. The clinical superiority of this product is similar to the clinical superiority lantus demonstrated a decade ago and Lantus is now a nearlt $8 billion product. If safety issues do not casue concerns this product has potentil to replace Lantus as the best selling insulin product. I do not expect that but statistically significant HbA1c reductions = $$$$
    28 Sep 2014, 11:13 PM Reply Like
  • derrickthms182
    , contributor
    Comments (715) | Send Message
    Very true indeed. Hopefully MNKD/SNY can take the new monopoly and leave Lilly in the dust.
    5 Sep 2014, 03:54 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs